Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine

Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (AB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Ang, Fang L.I., Rowland, Andrew, Modi, Natansh D., McKinnon, Ross A., Sorich, Michael J., Hopkins, Ashley M.
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7097941/
https://ncbi.nlm.nih.gov/pubmed/32231738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.41996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados